MPC1 and neoplasm: Using two independent cohorts of PDAC (resectable and metastatic), we validated the association of low MPC1 and clinicopathologic parameters of aggressive PDAC, including lower MPC protein subunit expression in basal-like tumors, further supporting the notion that MPC1 may inhibit tumor metastatic potential.